Clinical Trial Update: A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gemcitabine, pembrolizumab, and IMM-101 as first-line therapy for metastatic pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• IMM 101
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Karen Carty | Conditions: Neoplasms Pancreatic | Phase 2 | Status: WITHDRAWN